title: Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
authors.affiliation: Newport Chest Clinic, U.K.
authors.forename: G
authors.initials: G
authors.lastname: Anderson
authors.forename: M
authors.initials: M
authors.lastname: Clavel
authors.forename: J
authors.initials: J
authors.lastname: Smyth
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
authors.forename: M
authors.initials: M
authors.lastname: Gracia
authors.forename: A S
authors.initials: AS
authors.lastname: Planting
authors.forename: O
authors.initials: O
authors.lastname: Dalesio
authors.forename: A
authors.initials: A
authors.lastname: Kirkpatrick
authors.forename: G
authors.initials: G
authors.lastname: McVie
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D004611:Ellipticines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007364:Intercalating Agents / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; D007364:Intercalating Agents; C027767:elliptinium